Need for standardising adverse event reporting in testosterone trials

Evidence-Based Medicine

Volumn 19, Issue 1, 2014, Pages 32-33

  Basaria, Shehzad ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ANDROGEN DEPRIVATION THERAPY; ANDROGEN THERAPY; HEMATOCRIT; HUMAN; HYPOGONADISM; INTERVENTION STUDY; META ANALYSIS; NOTE; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC);

CARDIOVASCULAR DISEASES; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TESTOSTERONE;

EID: 84895540660     PISSN: 13565524     EISSN: 14736810     Source Type: Journal    
DOI: 10.1136/eb-2013-101402     Document Type: Note

References (6)

1. Spitzer M, Huang G, Basaria S, et al. Risks and benefits of testosterone therapy in older men. Nat Rev Endocrinol 2013;9: 414-24.
2. Handelsman DJ. Pharmacoepidemiology of testosterone prescribing in Australia, 1992-2010. Med J Aust 2012;196: 642-5.
3. Basaria S. Reproductive aging in men. Endocrinol Metab Clin North Am 2013;42: 255-70.
4. Shahani S, Braga-Basaria M, Basaria S. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis. J Clin Endocrinol Metab 2008;93: 2042-9.
5. Eyben FE, Graugaard C, Vaeth M. All-cause mortality and mortality of myocardial infarction for 989 legally castrated men. Eur J Epidemiol 2005;20: 863-9.
6. Ioannidis JP, Evans SJ, Gøtzsche PC, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med 2004;141: 781-8.